Bortezomib Completed Phase 2 Trials for Diffuse Large B-Cell Lymphoma (DLBCL) Treatment

CompletedTreatment2 IdentifierTitleDrugs
NCT01848132Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.
NCT01040871Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma